He Qianqian, Lai Ze, Zhai Zhengyao, Zou Beibei, Shi Yangkai, Feng Chao
Department of Cardiology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
Front Cardiovasc Med. 2025 Jan 13;11:1501735. doi: 10.3389/fcvm.2024.1501735. eCollection 2024.
Diabetic cardiomyopathy (DCM) is one of the most prevalent and severe complications associated with diabetes mellitus (DM). The onset of DCM is insidious, with the symptoms being obvious only in the late stage. Consequently, the early diagnosis of DCM is a formidable challenge which significantly influences the treatment and prognosis of DCM. Thus, it becomes imperative to uncover innovative approaches to facilitate the prompt identification and diagnosis of DCM. On the traditional clinical side, we tend to use serum biomarkers as well as imaging as the most common means of diagnosing diseases because of their convenience as well as affordability. As we delve deeper into the mechanisms of DCM, a wide variety of biomarkers are becoming competitive diagnostic indicators. Meanwhile, the application of multiple imaging techniques has also made efforts to promote the diagnosis of DCM. Besides, the spurt in sequencing technology has made it possible to give hints about disease diagnosis from the genome as well as the transcriptome, making diagnosis less difficult, more sensitive, and more predictive. Overall, sequencing technology is expected to be the superior choice of plasma biomarkers for detecting lesions at an earlier stage than imaging, and its judicious utilization combined with imaging technologies will lead to a more sensitive diagnosis of DCM in the future. Therefore, this review meticulously consolidates the progress and utilization of various biomarkers, imaging methods, and sequencing technologies in the realm of DCM diagnosis, with the aim of furnishing novel theoretical foundation and guide future research endeavors towards enhancing the diagnostic and therapeutic landscape of DCM.
糖尿病性心肌病（DCM）是糖尿病（DM）最常见且最严重的并发症之一。DCM起病隐匿，症状仅在晚期才明显。因此，DCM的早期诊断是一项艰巨的挑战，这对DCM的治疗和预后有重大影响。所以，迫切需要找到创新方法以促进DCM的快速识别和诊断。在传统临床方面，由于血清生物标志物和影像学检查方便且经济，我们倾向于将其作为最常用的疾病诊断手段。随着我们对DCM发病机制的深入研究，各种各样的生物标志物正成为有竞争力的诊断指标。同时，多种成像技术的应用也为促进DCM的诊断做出了努力。此外，测序技术的飞速发展使得从基因组和转录组层面为疾病诊断提供线索成为可能，使诊断变得不那么困难、更敏感且更具预测性。总体而言，测序技术有望成为比影像学更早检测到病变的血浆生物标志物的首选，其与成像技术的合理结合将在未来实现对DCM更灵敏的诊断。因此，本综述精心总结了各种生物标志物、成像方法和测序技术在DCM诊断领域的进展与应用，旨在提供新的理论基础，并指导未来的研究工作，以改善DCM的诊断和治疗前景。
